首页> 外国专利> METHOD OF PREDICTING EFFICIENCY OF COMBINED THERAPY OF CHRONIC HEPATITIS C IN CHILDREN

METHOD OF PREDICTING EFFICIENCY OF COMBINED THERAPY OF CHRONIC HEPATITIS C IN CHILDREN

机译:预测儿童慢性丙型肝炎联合治疗效率的方法

摘要

FIELD: medicine.SUBSTANCE: invention represents method of predicting efficiency of combined therapy of CHC in children, which includes analysis of absolute quantity of neutrophils of blood, characterized by the fact that before starting therapy initial level of absolute quantity of neutrophils is determined, with level 2000-3400/mcl is considered to be positive predictor of obtaining initial virological remission, and level, which exceeds 3500/mcl, is considered to be negative predictor of obtaining remission; in dynamics after 12 and 24 weeks from the start of combined therapy level of absolute quantity of neutrophils is determined, and if level of neutrophils ?1400/mcl, conclusion about positive prediction of therapy efficiency is made, and if level of absolute number of neutrophils ?2500/mcl, achievement of initial virological remission is unlikely.EFFECT: application of invention makes it possible to predict efficiency of combined therapy of CHC with pegylated IFN?-2b and ribavirin in children and makes it possible to avoid durative irrational treatment, prevent development of complications.2 dwg, 2 tbl, 3 ex
机译:领域:药物:本发明代表了预测儿童CHC联合疗法疗效的方法,该方法包括分析血液中性粒细胞的绝对量,其特征在于在开始治疗之前确定中性粒细胞绝对量的初始水平, 2000-3400 / mcl水平被认为是获得初始病毒学缓解的阳性指标,而水平超过3500 / mcl被认为是获得初步病毒学缓解的阴性指标;联合治疗开始后12周和24周的动力学变化,确定中性粒细胞的绝对量水平,如果中性粒细胞水平≥1400/ mcl,则得出关于治疗效率的阳性预测的结论,以及中性粒细胞绝对数目水平≤2500/ mcl,不可能实现最初的病毒学缓解。效果:本发明的应用使得可以预测儿童聚乙二醇化IFNγ-2b和利巴韦林联合使用CHC的疗效,并且可以避免持续的不合理治疗,预防2 dwg,2 tbl,3 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号